Effectiveness of the Vertebra complex in patients with non-specific back pain (a complication of osteochondrosis): a randomized controlled clinical trial

Dovgan O.O.,Kirdoglo G.K.

Головна
Публікації
Effectiveness of the Vertebra complex in patients with non-specific back pain (a complication of osteochondrosis): a randomized controlled clinical trial

29 березня 2024

559

Neurology and Psychiatry

Dovgan O.O.

Kirdoglo G.K.

УДК: 616.8-009.7

DOI: 10.32471/umj.1680-3051.160.252654

Ключові слова :

back pain,

osteochondrosis,

Vertebra complex

Спеціальності :

Neurology and Psychiatry

Резюме

Purpose: to evaluate the effect of the Vertebra complex in patients with back pain (a complication of osteochondrosis).

Object and research methods. A randomized controlled clinical trial with a double-blind placebo-controlled period lasting 3 months was conducted. The study involved 30 (16 men and 14 women) patients aged 18–65 (38.4±3.8) years old with complications of osteochondrosis who underwent a rehabilitation course at the Center for Kinesitherapy and Rehabilitation «Vyshcha Liga». The participants were randomized into two groups: in the 1st group, the Vertebra complex was prescribed for 1 sachet 2 times a day for 3 months with standard therapy (non-steroidal anti-inflammatory drugs, muscle relaxants, group B vitamins); the 2nd group received only standard therapy. All patients worked out for 3 months in the hall of rehabilitation simulators, with dosed physical activity.

The results. All study participants noted a decrease in the severity of pain within 3 months, but patients who used the Vertebra complex noted a more stable pain relief effect and in a shorter period of time.

Conclusion. The inclusion of the Vertebra complex in the treatment regimen in patients with complications of osteochondrosis has a clinical advantage compared to patients who received only standard therapy.

References

1. Driscoll T., Jacklyn G., Orchard J. et al. (2014) The global burden of occupationally related low back pain: estimates from the Global Burden of Disease 2010 study. Ann. Rheum. Dis., 2014: 1–7. doi: 10.1136/annrheumdis-2013-204631.
2. Vos T., Alemu Abajobir A., Hassen Abate K. et al. (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 390: 1211–1259. doi: 10.1016/S0140-6736(17)32154-2.
3. Meucci R.D., Fassa A.G., Muller N., Faria X. (2015) Prevalence of chronic low back pain: systematic review. Rev. Saúde Pública, 49(73): 1–10. doi: 10.1590/S0034-8910.2015049005874.
4. Shmagel A., Foley R., Ibrahim H. (2017) Epidemiology of chronic low back pain in US adults: National Health and Nutrition Examination Survey 2009–2010. Arthritis Care Res., 68(11): 1688–1694. doi: 10.1002/ acr.22890.
5. Веселовский В.П. (1991) Практическая вертебро-неврология и мануальная терапия. Рига, 341 с.
6. Colombini A., Lombardi G., Corsi M.M., Banfi G. (2008) Pathophysiology of the human intervertebral disc. Int. J. Biochem. Cell Biol., 40(5): 837–842.
7. Miller J., Schmatz C., Schultz A. (1988) Lumbar disc degeneration: Correlation with Age, Sex, and Spine Level in 600 Autopsy Specimens. Spine, 13(2): 173–178.
8. Hadjipavlou A.G., Tzermiadianos M.N., Bogduk N., Zindrick M.R. (2008) The pathophysiology of disc degeneration. J. Bone Joint Surg. Br., 90: 12611270.
9. Tat S.K., Pelletier J.-P., Verges J. et al. (2007) Chondroitin and glucosamine sulfate in combination decrease the proresorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. Arthritis Res. Ther., 9(6): R117. doi: 10.1186/ar2325.
10. Cutolo M., Berenbaum F., Hochberg M. et al. (2015) Commentary on recent therapeutic guidelines for osteoarthritis. Semin. Arthritis Rheum., 44(6): 611–617. doi: 10.1016/j.semarthrit.2014.12.003.
11. Scarpellini M., Lurati A., Vignati G. et al. (2008) Biomarkers, type II collagen, glucosamine and chondroitin sulfate in osteoarthritis follow-up: the Magenta osteoarthritis study. J. Orthop. Traumatol., 9(2): 81–87. doi: 10.1007/s10195-008-0007-5.
12. Lubis A.M.T., Siagian C., Wonggokusuma E. et al. (2017) Comparison of Glucosamine-Chondroitin Sulfate with and without Methylsulfonylmethane in Grade I-II Knee Osteoarthritis: A Double Blind Randomized Controlled Trial. Acta Med. Indones, 49(2): 105–111.
13. Ezaki J., Hashimoto M., Hosokawa Yu., Ishimi Y. (2013) Assessment of safety and efficacy of methylsulfonylmethane on bone and knee joints in osteoarthritis animal model. J. Bone Miner. Metab., 31(1): 16–25. doi: 10.1007/s00774-012-0378-9.
14. Chrubasik S., Model A., Black A., Pollak S. (2003) A randomized double-blind pilot study comparing Doloteffin and Vioxx in the treatment of low back pain. Rheumatol. (Oxford), 42(1): 141–148. doi: 10.1093/rheumatology/keg053.